NCI-H727（人肺支气管良性肿瘤）
CBP60182
询 价
索取STR
产品描述
产品数据库
| I. General information | |
| Synonyms: | NCI-H727 |
| Background: | This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from tissue taken prior to therapy. |
| Species: | Homo sapiens, human |
| Tissue: | lung, bronchus |
| Disease: | carcinoid |
| Gender: | female, 65 years, Caucasian |
| Morphology: | epithelial |
| Growth Mode: | adherent |
| DNA Profile: | Amelogenin: X CSF1PO: 11,12 D13S317: 11 D16S539: 11,13 D5S818: 11,12 D7S820: 8,10 THO1: 8 TPOX: 8 vWA: 14,15 Cobioer’s Cell Line Authentication Service |
| Culture Medium: |
RPMI-1640+20%FBS NCI-H727完全培养基，# CBP60182M |
| Cryopreservation medium: | 90%FBS+10%DMSO |
| Receptor Expression: | epidermal growth factor (EGF) |
| Genes Expressed: | neuromedin B (NMB) |
| Cellular Products: | neuromedin B (NMB) |
| Comments: | This is the best differentiated of the available bronchial carcinoid lines.The cells express easily detectable levels of p53 mRNA compared to levels found in normal lung.The cells are able to synthesize the peptide NMB (at 0.1 pmol/mg protein), but not the gastrin releasing peptide (GRP). The cell line secretes a parathyroid hormone-like protein which is calcium stimulated through a protein kinase C pathway.Growth of NCI-H727 cells is inhibited by epidermal growth factor (EGF) receptor monoclonal antibodies. For more information, please contact Cobioer (4008-750-250). |
